

Fernando Carceller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8662234/publications.pdf>

Version: 2024-02-01

38
papers

565
citations

758635

12
h-index

676716

22
g-index

42
all docs

42
docs citations

42
times ranked

1138
citing authors

#	ARTICLE	IF	CITATIONS
1	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	7.7	157
2	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. <i>European Journal of Cancer</i> , 2019, 121, 224-235.	1.3	44
3	Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. <i>Cancer Medicine</i> , 2017, 6, 2606-2624.	1.3	42
4	Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort. <i>European Radiology</i> , 2017, 27, 345-353.	2.3	40
5	Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 109-121.	1.4	30
6	A case series of Diffuse Glioneuronal Tumours with Oligodendroglioma-like features and Nuclear Clusters (DGONC). <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 464-467.	1.8	27
7	Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients. <i>Neuro-Oncology Advances</i> , 2021, 3, v03d013.	0.4	27
8	Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma. <i>Cancer Discovery</i> , 2022, 12, 416-431.	7.7	25
9	Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study. <i>European Radiology</i> , 2015, 25, 2641-2650.	2.3	22
10	Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study. <i>European Journal of Cancer</i> , 2016, 67, 130-140.	1.3	17
11	Challenging the indiscriminate use of temozolomide in pediatric high-grade gliomas: A review of past, current, and emerging therapies. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28011.	0.8	17
12	Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 3424-3435.	0.4	15
13	DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition. <i>Cancer Discovery</i> , 2022, 12, 712-729.	7.7	15
14	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. <i>Cancer Research</i> , 2019, 79, 2978-2991.	0.4	13
15	Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. <i>European Journal of Cancer</i> , 2022, 162, 209-220.	1.3	12
16	Clinical research tools in pediatric oncology: challenges and opportunities. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 149-160.	2.7	9
17	Post-radiotherapy apparent diffusion coefficient (ADC) in children and young adults with high-grade gliomas and diffuse intrinsic pontine gliomas. <i>Pediatric Hematology and Oncology</i> , 2019, 36, 103-112.	0.3	7
18	Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1400-1406.	0.8	6

#	ARTICLE	IF	CITATIONS
19	High grade gliomas in young children: The South Thames Neuro-Oncology unit experience and recent advances in molecular biology and targeted therapies. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 707-721.	0.3	6
20	PDTM-33. ATRX LOSS CONFERS ENHANCED SENSITIVITY TO COMBINED PARP INHIBITION AND RADIOTHERAPY IN PAEDIATRIC GLIOBLASTOMA MODELS. <i>Neuro-Oncology</i> , 2018, 20, vi210-vi211.	0.6	5
21	High-dose etoposide and cyclophosphamide in adults and children with primary refractory and multiply relapsed acute leukaemias: The Royal Marsden experience. <i>Leukemia Research</i> , 2019, 85, 106217.	0.4	5
22	Tumour-agnostic drugs in paediatric cancers. <i>British Journal of Cancer</i> , 2020, 122, 1425-1427.	2.9	4
23	Constitutional mismatch repair deficiency (CMMRD) presenting with high-grade glioma, multiple developmental venous anomalies and malformations of cortical development—a multidisciplinary/multicentre approach and neuroimaging clues to clinching the diagnosis. <i>Child's Nervous System</i> , 2020, 37, 2375-2379.	0.6	3
24	Long-term survivors of diffuse intrinsic pontine glioma (DIPG): myth or reality. <i>Translational Cancer Research</i> , 2019, 8, 343-343.	0.4	3
25	Feasibility and applicability of diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging in routine assessments of children with high-grade gliomas. <i>Pediatric Blood and Cancer</i> , 2017, 64, 279-283.	0.8	2
26	Outcome of children and adolescents with central nervous system tumors in phase I trials. <i>Journal of Neuro-Oncology</i> , 2018, 137, 83-92.	1.4	2
27	MODL-20. A BIOBANK OF ~100 PATIENT-DERIVED MODELS REPRESENTING BIOLOGICAL HETEROGENEITY AND DISTINCT THERAPEUTIC DEPENDENCIES IN PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. <i>Neuro-Oncology</i> , 2020, 22, iii414-iii415.	0.6	2
28	HGG-23. DRUG SCREENING LINKED TO MOLECULAR PROFILING IDENTIFIES NOVEL DEPENDENCIES IN PATIENT-DERIVED PRIMARY CULTURES OF PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. <i>Neuro-Oncology</i> , 2018, 20, i93-i94.	0.6	1
29	How to address challenges and opportunities in pediatric cancer drug development?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 869-872.	2.5	1
30	Access to early-phase clinical trials for children with relapsed and refractory neuroblastoma: A multicentre international study. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29551.	0.8	1
31	LGG-09. A Nationwide Service Evaluation of Safety, Radiologic and Visual Outcome Refining Bevacizumab-based Treatments in Children with Progressive Low-Grade Glioma. <i>Neuro-Oncology</i> , 2022, 24, i89-i89.	0.6	1
32	PDTM-34. TARGETING H3.3G34R/V RE-WIRING OF THE EPIGENOME IN PAEDIATRIC GLIOBLASTOMA OF CHILDREN AND YOUNG ADULTS. <i>Neuro-Oncology</i> , 2018, 20, vi211-vi211.	0.6	0
33	EAPH-05. MOLECULAR PROFILING AND IDENTIFICATION OF TARGETED THERAPIES FOR CHILDREN AND YOUNG ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMOURS IN THE UNITED KINGDOM. <i>Neuro-Oncology</i> , 2018, 20, i66-i66.	0.6	0
34	PDTM-31. DRUG SCREENING LINKED TO MOLECULAR PROFILING IDENTIFIES NOVEL DEPENDENCIES IN PATIENT-DERIVED PRIMARY CULTURES OF PAEDIATRIC HIGH GRADE GLIOMA AND DIPG. <i>Neuro-Oncology</i> , 2018, 20, vi210-vi210.	0.6	0
35	HGG-13. SURVIVAL OUTCOMES OF CHILDREN AND ADOLESCENTS WITH BI-THALAMIC GLIOMAS: THE SOUTH THAMES NEURO-ONCOLOGY UNIT EXPERIENCE. <i>Neuro-Oncology</i> , 2018, 20, i91-i91.	0.6	0
36	Radiological pseudoprogression post-radiotherapy in a child with pineal germ cell tumour. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28407.	0.8	0

#	ARTICLE	IF	CITATIONS
37	EXTH-46. ARTIFICIAL INTELLIGENCE-BASED IDENTIFICATION OF COMBINED VANDETANIB AND EVEROLIMUS IN THE TREATMENT OF ACVR1-MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii97-ii97.	0.6	0
38	Is it possible to achieve long-term survival in relapsed intracranial non-germinomatous germ cell tumours?. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	0.8	0